The mission of the Bioinformatics Share Resource (BISR) is to provide cutting edge bioinformatics services and collaborative research support to MCCC investigators engaged in genomics studies with high impact on the care of cancer patients. The allied BISR led by Dr. Jean-Pierre Kocher currently counts 7 MS and Ph.D. level allied health bioinformaticians. The service lines offered by the BIC fall in 4 categories: i) preprocessing of omics data including several workflow dedicated to Next Generation Sequencing data analysis, ii) data annotation services critical for the first level interpretation of preprocessed genomics data, iii) data management solution for the integration of large genomics, proteomics and metabolomics datasets iv) data collection services from internal and external data sources (Mayo Biobank, TCGA, GEO, etc.). The BISR also facilitates the collaborative research opportunity between MCCC faculty and Bioinformatics Faculty. The BISR has forged a tight patnership with the Research IT Department for the development of Bioinformatics workflows and systems. About 10 analysts programmers of the Research IT department are supporting the BISR at no additional charge to MCCC. Over the last 5 years, the BISR has worked with 121 MCCC investigators on more than 775 projects. About 60% of these investigators had or have peer reviewed funding. The BISR has faciliated the collaborative engagement of more than 13 bioinformatics faculty on 39 projects led by MCCC investigators. During the same period, BISR faculty and allied health staff were coauthor on over 75 publications during the project period with MCCC investigators. In addition, over the last year, BSIR faculty were listed as key personal on more than 60 submitted grants. BSIR faculty are engaged with the Prostate, Breast, Lymphoma and Ovarian Spores. In the future, the BISR will pursue the development of preprocessing workflows, further implement or develop methods for the advanced interpretation of omics data as well as maintain its educational activities. BISR is now located on all 3 Mayo sites: Mayo Clinic Rochester (MCR), Mayo Clinic Arizona (MCA), and Mayo Clinic Florida (MCF).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682946
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$193,561
Indirect Cost
$71,929
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434

Showing the most recent 10 out of 1129 publications